Company intelligence / Profile preview

Invea Therapeutics

Guilford, CT, United Statesinveatx.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 2

Overview

Invea’s lead asset INVA8001 is a highly selective chymase inhibitor targeting mast cell-driven inflammation in IMIDs such as atopic dermatitis and chronic urticaria. The compound was previously evaluated by Daiichi Sankyo in a Phase 2 trial that did not meet its primary endpoint; Invea plans a redesigned Phase 2b trial addressing prior limitations. Their second candidate, INVA8003, targets ASC for multi-inflammasome inhibition and is in preclinical development. No approved products yet[5].

Therapeutic areas: ImmunologyDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

INVA8003

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Daiichi Sankyo Company (in-license of lead asset)[5]

Beyond the preview

Go deeper on Invea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invea Therapeutics.

Explore the full profile